Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Fallopian Tube Neoplasms 4Carcinoma 4Carcinoma, Renal Cell 3Sarcoma 2Glioblastoma 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Stomach Neoplasms 1Sarcoma, Endometrial Stromal 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Oligodendroglioma 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Kidney Diseases 1Hemangiosarcoma 1Gliosarcoma 1Glioma 1Congenital Abnormalities 1

Interventions

trebananib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Hepatocellular Carcinoma × trebananib × Clear all
NCT00872014 2016-04-04

A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer

Amgen

Phase 2 Completed
60 enrolled
Gastrointestinal

Advanced Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡